1
|
Odabas GP, Aslan K, Suna PA, Kendirli PK, Erdem Ş, Çakır M, Özcan A, Yılmaz E, Karakukcu M, Donmez-Altuntas H, Yay AH, Deniz K, Altay D, Arslan D, Canatan H, Eken A, Unal E. Alantolactone ameliorates graft versus host disease in mice. Int Immunopharmacol 2024; 128:111560. [PMID: 38246003 DOI: 10.1016/j.intimp.2024.111560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 12/17/2023] [Accepted: 01/15/2024] [Indexed: 01/23/2024]
Abstract
The anti-inflammatory and immunosuppressive drugs which are used in the treatment of Graft-versus-Host Disease (GVHD) have limited effects in controlling the severity of the disease. In this study, we aimed to investigate the prophylactic effect of Alantolactone (ALT) in a murine model of experimental GVHD. The study included 4 BALB/c groups as hosts: Naïve (n = 7), Control GVHD (n = 16), ALT-GVHD (n = 16), and Syngeneic transplantation (n = 10). Busulfan (20 mg/kg/day) for 4 days followed by cyclophosphamide (100 mg/kg/day) were administered for conditioning. Allogeneic transplantation was performed with cells collected from mismatched female C57BL/6, and GVHD development was monitored by histological and flow cytometric assays. Additionally, liver biopsies were taken from GVHD patient volunteers between ages 2-18 (n = 4) and non-GVHD patients between ages 2-50 (n = 5) and cultured ex vivo with ALT, and the supernatants were used for ELISA. ALT significantly ameliorated histopathological scores of the GVHD and improved GVHD clinical scores. CD8+ T cells were shown to be reduced after ALT treatment. More importantly, ALT treatment skewed T cells to a more naïve phenotype (CD62L+ CD44-). ALT did not alter Treg cell number or frequency. ALT treatment appears to suppress myeloid cell lineage (CD11c+). Consistent with reduced myeloid lineage, liver and small intestine levels of GM-CSF were reduced in ALT-treated mice. IL-6 gene expression was significantly reduced in the intestinal tissue. Ex vivo ALT-treated liver biopsy samples from GVHD patients showed a trend of decrease in pro-inflammatory cytokines but there was no statistical significance. Collectively, the data indicated that ALT may have immunomodulatory actions in a preclinical murine GVHD model.
Collapse
Affiliation(s)
- Gul Pelin Odabas
- Erciyes University School of Medicine, Department of Pediatrics, Division of Pediatric Hematology and Oncology, Kayseri, Turkiye
| | - Kubra Aslan
- Erciyes University School of Medicine, Department of Medical Biology, Kayseri, Turkiye; Betul-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkiye
| | - Pinar Alisan Suna
- Erciyes University School of Medicine, Department of Histology and Embryology, Kayseri, Turkiye
| | - Perihan Kader Kendirli
- Abdullah Gül University, School of Life and Natural Sciences, Department of Bioengineering, Kayseri, Turkiye
| | - Şerife Erdem
- Erciyes University School of Medicine, Department of Medical Biology, Kayseri, Turkiye; Betul-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkiye
| | - Mustafa Çakır
- Erciyes University School of Medicine, Department of Medical Biology, Kayseri, Turkiye; Betul-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkiye; Van Yuzuncu Yıl University, School of Medicine, Department of Medical Biology, Van, Turkiye
| | - Alper Özcan
- Erciyes University School of Medicine, Department of Pediatrics, Division of Pediatric Hematology and Oncology, Kayseri, Turkiye
| | - Ebru Yılmaz
- Erciyes University School of Medicine, Department of Pediatrics, Division of Pediatric Hematology and Oncology, Kayseri, Turkiye; Erciyes University, Institute of Health Sciences, Department of Blood Banking and Transfusion Medicine, Kayseri, Turkey
| | - Musa Karakukcu
- Erciyes University School of Medicine, Department of Pediatrics, Division of Pediatric Hematology and Oncology, Kayseri, Turkiye
| | - Hamiyet Donmez-Altuntas
- Erciyes University School of Medicine, Department of Medical Biology, Kayseri, Turkiye; Betul-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkiye
| | - Arzu Hanim Yay
- Betul-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkiye; Erciyes University School of Medicine, Department of Histology and Embryology, Kayseri, Turkiye
| | - Kemal Deniz
- Erciyes University School of Medicine, Department of Pathology, Kayseri, Turkiye
| | - Derya Altay
- Erciyes University School of Medicine, Department of Pediatric Gastroenterology, Kayseri, Turkiye
| | - Duran Arslan
- Erciyes University School of Medicine, Department of Pediatric Gastroenterology, Kayseri, Turkiye
| | - Halit Canatan
- Erciyes University School of Medicine, Department of Medical Biology, Kayseri, Turkiye; Betul-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkiye
| | - Ahmet Eken
- Erciyes University School of Medicine, Department of Medical Biology, Kayseri, Turkiye; Betul-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkiye.
| | - Ekrem Unal
- Erciyes University School of Medicine, Department of Pediatrics, Division of Pediatric Hematology and Oncology, Kayseri, Turkiye; Erciyes University, Institute of Health Sciences, Department of Blood Banking and Transfusion Medicine, Kayseri, Turkey; Hasan Kalyoncu University School of Health Sciences, Department of Nursing, Gaziantep, Turkiye; Medical Point Hospital Hematology and Oncology Clinic, Gaziantep, Turkiye.
| |
Collapse
|
2
|
Analysis of Cdcs1 colitogenic effects in the hematopoietic compartment reveals distinct microbiome interaction and a new subcongenic interval active in T cells. Mucosal Immunol 2019; 12:691-702. [PMID: 30659231 DOI: 10.1038/s41385-019-0133-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 12/14/2018] [Accepted: 12/26/2018] [Indexed: 02/04/2023]
Abstract
Disease activity in Interleukin-10-deficient (Il10-/-) mice, a model for IBD, depends on genetic background and microbiome composition. B6.129P2/JZtm-Il10tm1Cgn (B6-Il10-/-) mice are partially resistant to colitis, whereas mice carrying the Cdcs1C3Bir haplotype on chromosome 3, B6.Cg-Il10tm1CgnMMU3(D3Mit11-D3Mit348)/JZtm (BC-R3-Il10-/-), are susceptible. This study was performed to clarify Cdcs1 and candidate gene effects on the colitogenic potential of hematopoietic cells using bone marrow (BM) and T-cell transfer models. Acute and chronic graft versus host reaction was excluded by high-density genotyping, in vitro and in vivo approaches. BM-chimeras were created with animals housed in two barriers (I and II) with distinct microbiota composition as identified by sequencing. BM-chimeras of all groups developed comparable moderate-to-severe colitis in Barrier I, however, in Barrier II only recipients of BC-R3-Il10-/- BM. Subsequent adoptive T cell transfers pointed to a new subcongenic interval within Cdcs1 affecting their colitogenic potential. Transfers excluded Larp7 and Alpk1 but highlighted Ifi44 as potential candidate genes. In this model-system, colitis development after cell transfer heavily depends on microbiome, though Cdcs1 acts mainly independently in hematopoietic cells. A new subcongenic interval, provisionally named Cdcs1.4, modifies colitogenic T cell function. Within this locus, Ifi44 represents an important candidate gene for colitis expression.
Collapse
|
3
|
Fan X, Guo D, Cheung AM, Poon ZY, Yap CS, Goh SE, Guo D, Li H, Bari S, Li S, Lim KH, Hwang WYK. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease. Biol Blood Marrow Transplant 2018; 24:1971-1980. [DOI: 10.1016/j.bbmt.2018.05.029] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Accepted: 05/22/2018] [Indexed: 01/06/2023]
|